Epigene Labs is a technology company.
Epigene Labs has raised $2.0M across 1 funding round.
Key people at Epigene Labs.
Epigene Labs has raised $2.0M in total across 1 funding round.
Key people at Epigene Labs.
Epigene Labs is a techbio company founded in 2019 that develops the mCUBE platform, an AI-powered solution for aggregating, curating, and analyzing multi-dimensional genomic and multi-omic data to accelerate precision oncology research and drug development[1][2][3][4][5]. The platform serves biopharma companies, biotech firms, cancer research institutes, and academic groups by transforming fragmented public and private datasets—now spanning over 2 million curated cancer profiles from 100,000 patient samples across 30+ cancer types—into unified disease atlases for applications like target discovery, biomarker identification, patient selection, and clinical trial design[2][4][5]. It solves the challenge of data fragmentation in oncology R&D, often reducing research timelines from months to days, with recent expansions including off-the-shelf data products for smaller biotechs and explorations into immunology and neurology[2][4].
Epigene Labs was founded in 2019 by co-founder and CEO Akpéli Nordor, with initial incubation at Harvard Innovation Labs before launching in France, backed by supporters like Station F, Agoranov, Cancer Campus, AstraZeneca, and European investors including the EIC Accelerator and European Innovation Council[1][2][3]. The idea emerged from seven years of scientific innovation in AI and bioinformatics, focusing on curating fragmented omic data into actionable insights for immunotherapy targets and biomarkers in oncology, drawing on the founders' expertise in data science, software engineering, biology, and oncology[1][2][4]. Early traction came from building complementary teams across Paris and Boston, securing seed funding, and demonstrating rapid impacts in immuno-oncology R&D programs at leading institutions[1][2][3].
Epigene Labs rides the precision medicine and AI-in-biotech wave, capitalizing on explosive growth in multi-omic data from public databases amid rising demand for faster oncology drug discovery amid complex, anatomically diverse cancers[1][2][4][5]. Timing aligns with advancements in immunotherapy and next-gen modalities like antigen-targeting, where fragmented data has bottlenecked R&D; market forces like biopharma's push for data-driven efficiency and regulatory emphasis on molecular definitions favor scalable platforms like mCUBE[2][4]. The company influences the ecosystem by democratizing high-resolution disease atlases, empowering smaller biotechs/academics, and expanding beyond oncology to immunology/neurology, positioning techbio as a key accelerator in global precision oncology[2][6].
Epigene Labs is poised for expansion with its 2-million-profile milestone unlocking broader therapeutic applications and commercial data products, potentially fueling Series A funding and partnerships with big pharma[2][3]. Trends like AI-augmented intelligence, multi-omic integration, and personalized therapies will propel growth, especially as data scale enables novel biology insights previously unreachable[2][4]. Its dual Paris-Boston presence and interdisciplinary team could evolve it into a category leader in disease atlases, amplifying impact across R&D pipelines and redefining precision oncology's data foundation—building directly on its mission to turn genomic mines into drug discovery edges[5].
Epigene Labs has raised $2.0M in total across 1 funding round.
Epigene Labs's investors include XAnge.
Epigene Labs has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $2.0M Seed | XAnge |